Monte Rosa Therapeutics, Inc. — All Filings
329 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
144/A
3
4
424B4
424B5
8-A12B
8-K
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
PRE 14A
S-1
S-1/A
S-1MEF
S-3
S-3ASR
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | 4 | 0000950170-24-106532 | Sep 13, 2024 | Sep 11, 2024 |
| 4 | 4 | 0000950170-24-106387 | Sep 13, 2024 | — |
| SC 13D/A | SC 13D/A | 0001193125-24-198980 | Aug 12, 2024 | — |
| SC 13D/A | NEW ENTERPRISE ASSOCIATES 17, L.P. -- MONTE ROSA THERAPEUTICS 13D/A(#2) | 0001072613-24-000618 | Aug 12, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-093296 | Aug 8, 2024 | Jun 30, 2024 |
| 8-K | 8-K | 0000950170-24-093294 | Aug 8, 2024 | — |
| 4 | 4 | 0000950170-24-082416 | Jul 9, 2024 | Jul 5, 2024 |
| 8-K | 8-K | 0000950170-24-078159 | Jun 27, 2024 | — |
| 4 | 4 | 0000950170-24-073265 | Jun 13, 2024 | Jun 12, 2024 |
| 4 | 4 | 0000950170-24-073064 | Jun 13, 2024 | Jun 12, 2024 |
| 4 | 4 | 0000950170-24-073059 | Jun 13, 2024 | Jun 12, 2024 |
| 4 | 4 | 0000950170-24-073062 | Jun 13, 2024 | Jun 12, 2024 |
| 4 | 4 | 0000950170-24-073063 | Jun 13, 2024 | Jun 12, 2024 |
| 4 | 4 | 0000950170-24-073073 | Jun 13, 2024 | Jun 12, 2024 |
| 8-K | 8-K | 0000950170-24-072407 | Jun 12, 2024 | — |
| 4 | 4 | 0000950170-24-069310 | Jun 5, 2024 | Jun 3, 2024 |
| 3 | 3 | 0000950170-24-069279 | Jun 5, 2024 | May 28, 2024 |
| 4 | 4 | 0000950170-24-069308 | Jun 5, 2024 | Jun 3, 2024 |
| 4 | 4 | 0000950170-24-069309 | Jun 5, 2024 | Jun 3, 2024 |
| 3 | 3 | 0000950170-24-069283 | Jun 5, 2024 | May 28, 2024 |
| 4 | 4 | 0000950170-24-069307 | Jun 5, 2024 | Jun 3, 2024 |
| 8-K | 8-K | 0001193125-24-149802 | May 30, 2024 | May 28, 2024 |
| 424B5 | 424B5 | 0001193125-24-140518 | May 16, 2024 | — |
| 8-K | 8-K | 0001193125-24-140533 | May 16, 2024 | May 15, 2024 |
| 424B5 | 424B5 | 0001193125-24-139354 | May 15, 2024 | — |
| SC 13D/A | NEW ENTERPRISE ASSOCIATES 17, L.P. -- MONTE ROSA THERAPEUTICS 13D/A(#1) | 0001072613-24-000471 | May 13, 2024 | — |
| 8-K | 8-K | 0000950170-24-056253 | May 9, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-056288 | May 9, 2024 | Mar 31, 2024 |
| 8-K | 8-K | 0000950170-24-052055 | May 2, 2024 | Apr 29, 2024 |
| 144 | — | 0001974158-24-000034 | May 1, 2024 | — |
| ARS | ARS | 0000950170-24-049093 | Apr 26, 2024 | Dec 31, 2023 |
| DEF 14A | DEF 14A | 0000950170-24-049065 | Apr 26, 2024 | — |
| DEFA14A | DEFA14A | 0000950170-24-049075 | Apr 26, 2024 | — |
| SC 13G/A | — | 0000080255-24-000836 | Apr 10, 2024 | — |
| 144 | — | 0001974158-24-000022 | Apr 10, 2024 | — |
| 10-K | 10-K | 0000950170-24-031150 | Mar 14, 2024 | Dec 31, 2023 |
| S-8 | S-8 | 0000950170-24-031455 | Mar 14, 2024 | — |
| 8-K | 8-K | 0000950170-24-031138 | Mar 14, 2024 | — |
| SC 13G/A | AMENDMENT NO. 3 | 0000929638-24-000644 | Feb 14, 2024 | — |
| SC 13G | SC 13G | 0001104659-24-023735 | Feb 14, 2024 | — |
| SC 13G/A | MONTE ROSA THERAPEUTICS, INC. | 0000902664-24-001601 | Feb 14, 2024 | — |
| SC 13G/A | — | 0000080255-24-000762 | Feb 14, 2024 | — |
| SC 13G/A | — | 0001086364-24-007037 | Feb 14, 2024 | — |
| SC 13G/A | — | 0000315066-24-001315 | Feb 9, 2024 | — |
| 8-K | 8-K | 0000950170-24-002696 | Jan 8, 2024 | — |
| 4 | FORM 4 SUBMISSION | 0001209191-24-000765 | Jan 4, 2024 | Jan 2, 2024 |
| 4 | FORM 4 SUBMISSION | 0001209191-24-000769 | Jan 4, 2024 | Jan 2, 2024 |
| 4 | FORM 4 SUBMISSION | 0001209191-24-000764 | Jan 4, 2024 | Jan 2, 2024 |
| 4 | FORM 4 SUBMISSION | 0001209191-24-000766 | Jan 4, 2024 | Jan 2, 2024 |
| 4 | FORM 4 SUBMISSION | 0001209191-24-000768 | Jan 4, 2024 | Jan 2, 2024 |